We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Oxford Nanopore Technologies Plc | LSE:ONT | London | Ordinary Share | GB00BP6S8Z30 | ORD GBP0.0001 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
4.70 | 3.22% | 150.50 | 150.10 | 150.50 | 152.00 | 145.80 | 146.20 | 526,081 | 15:40:18 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 169.67M | -154.51M | -0.1641 | -9.17 | 1.37B |
Date | Subject | Author | Discuss |
---|---|---|---|
21/5/2024 13:59 | With £400 Mil in cash the business is only valued at £600 Mil. This is why the shares will rerate imo Good luck | seball | |
21/5/2024 13:24 | Seball, at the moment it cannot seem to find a support level anywhere - perhaps if we drift back to 90 and this holds then we have the making of some support there but not it seems higher up and so why would someone want to buy in without some air cover in the form of a support base...nai etc I keep watching and waiting.... | takeiteasy | |
21/5/2024 13:11 | With LAT shares expiring early June this is ripe for a takeover. This valuation is ludicrous. ONT will not be staying at this price for long. BUY and HOLD. | seball | |
21/5/2024 13:01 | Time to shift totally to NYSELanguishing at this level is ridiculous. | luzley | |
21/5/2024 08:18 | Around 20 trading days remain before LAT shares expire. LC begins today. Clive Brown presents his technical update tomorrow, where we get to see some of the work produced by the recently expanded research teams. | bamboo2 | |
18/5/2024 18:08 | Turbot. Sample to answer review. "I don’t know if it ever will feel normal to place your samples on the machine and just go home 😀 It truly is walk away and come back next day and look at the sequencing report." | bamboo2 | |
16/5/2024 07:04 | Yes eeza US inflation | seball | |
15/5/2024 19:58 | US inflation rate dropped, I think. | eeza | |
15/5/2024 19:44 | seball, Which US news in particular? | bamboo2 | |
15/5/2024 17:05 | With today's news in the US and the LAT shares expiring June these are going to rerate. Buy now and hold this could easily go up 200% this year. | seball | |
13/5/2024 21:27 | Seems to be taking a breather. I've tried a bit but hold the substantive part from sub £1, which I hope we will not see again. | brucie5 | |
12/5/2024 12:02 | Wednesday 22/5/2024 sessions look interesting... 15:40 Nanopore Origins features the main inventors of Nanopore sequencing, 10 years after the first sequencers were made available. 17:45 Clive Brown takes the stand for the Technical Update. All these are normally recorded, and made available to view afterwards. There are dozens of other interesting events at London Calling, finishing on Friday 24 with a Clinical Applications day. Clinical applications are already becoming established in some hospitals. It is this market, that Gordon Sanghera mentioned should start to take off in 2025. | bamboo2 | |
10/5/2024 11:36 | Keeps on going... | brucie5 | |
10/5/2024 10:51 | through 120p would mean v little resistance to 140p | tsmith2 | |
09/5/2024 19:32 | Very few late reported trades in the past few trading days. I have never known it so quiet after 4.35 bst. Could further indicate seller is finished perhaps? | bamboo2 | |
08/5/2024 09:53 | These are the levels as I see them: 1.10 (50 wma just through) 1.30 (100wma) 1.60 (200wma). | brucie5 | |
08/5/2024 09:49 | BioMerieux Mcap is 11.8 bln. Anyone not thinking they will be looking to snap up ONT or merge is crazy. They bought a substantial amount of ONT in October at twice this price. No smoke without fire. BUY | seball | |
07/5/2024 10:09 | It's an interesting one and tends to illustrate the phenomenon of share prices that bomb towards the bottom of the curve, only to recover twice as quickly. Oxb an egregious example. These are very valuable companies in terms of IP and partnerships, with cash runways to BE. Cwr another to watch, I think. | brucie5 | |
07/5/2024 09:50 | I don't think swiftly to 150p is unrealistic | tsmith2 | |
05/5/2024 14:12 | On my chart, an eod close above 167 required to overcome the upper trendline and historical resistance. The next NCM is London Calling 2024, Tuesday 21st - Friday 24th May 2024. There should be a technical update around Thursday 23rd. I anticipate news on a number of fronts. By the middle of the year, recruitment in the commercial and research teams should be approaching target capacity, so there will be little excuse for lack of technical progress at the meeting. I hope that he Half year 2024 trading update on 24 July 2024 will provide evidence of an increase in sales. | bamboo2 | |
05/5/2024 12:02 | expecting a stronger rise next week. | tsmith2 | |
03/5/2024 14:03 | June but not sure of date??? Agree not long. This is a sitting duck at this price. They could get an offer of 300p but that would be robbery. Deutsche Bank initiates Oxford Nanopore with 'buy' - target 190 pence BUY | seball | |
03/5/2024 13:37 | When does the lock in period end and these become a takeover target? Not far away from memory? | the big fella | |
03/5/2024 13:18 | kash_3 May '24 - 09:44 - 1375 of 1379 0 1 0 Deutsche bank target £1.90 -------------------- Thanks. This would take it back to the not so recent past (this January) and back up to a full chart reversal on the 200smas. Then I would see £2 as the natural line of resistance. Such charts and situations take an age to ripen, but when they do you can observe their potential with OXB. I expect similar here in due course. Analogous to OXB/IM involvement at around the £4 level, Biomerieux was a buyer here of 3.5% at 2.38. That surely provides some kind of natural target price. | brucie5 | |
03/5/2024 10:49 | even if they crossed a threshold? | tsmith2 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions